Why Psychiatric Treatment Often Lacks a Plan for Stopping Medications — And What Patients Need to Know

When I first started taking an antidepressant as a teenager, no one talked to me or my parents about how I might eventually stop. Instead, the conversation was entirely centered on finding and starting the right medication. Since then, my prescription list has quietly grown — fluoxetine (Prozac) replaced with escitalopram (Lexapro), then venlafaxine (Effexor), the dose creeping upward, and eventually the addition of aripiprazole (Abilify), an antipsychotic used as an adjunct for treatment-resistant depression. Now, at 40, 8 years into sobriety and decades of mental health care, I’m beginning to question why my medications have only increased, never decreased.

This personal story reflects a widespread problem in mental health care: We have clear roadmaps for starting psychotropic medications, but very few for stopping them. The field is just beginning to develop guidelines for deprescribing, and these conversations often lack the voices of people with lived experience. Worse, there is a stunning lack of evidence documenting the long-term effects of these medications, even as they are increasingly used for years or decades in the real world.

For millions of Americans taking psychiatric medications, this gap has real consequences. This article explores why deprescribing is so challenging, what the research says, and what you can do to have a more informed conversation with your doctor.

The Growing Use of Psychiatric Medications — Without an Exit Plan

National data show that the number of prescriptions for psychiatric medications has risen significantly in recent years, even as research on their long-term benefits and risks remains limited. Antidepressants are usually prescribed during acute periods of distress, yet in the U.S., the median user will stay on them for approximately 5 years. The majority — 70% — will take them for more than 2 years. This is striking given that the evidence of effectiveness for antidepressants is generally derived from clinical trials ranging in length from 6 to 12 weeks.

In practice, treatment often defaults to continuation, not because it is always necessary, but because there are few established pathways for safely stopping. Unlike many other areas of medicine, there are few widely implemented or well-established standards for when and how to taper or discontinue psychiatric medications. Patients may feel reluctant to lead the charge, lest they be characterized as difficult, lacking insight, or “non-compliant.”

How This Affects Real People

For those who do consider stopping, the process is rarely straightforward. Many patients experience withdrawal symptoms, sometimes called “discontinuation syndrome.” In online patient communities, people report symptoms that can include anxiety, insomnia, and the “brain zaps” I’ve experienced. Research suggests that these withdrawal symptoms may be more common and longer-lasting than previously recognized.

These symptoms are often difficult to distinguish from relapse, creating a clinical gray area where both patients and providers may default to resuming medication. Without clear guidance, patients are often left to interpret withdrawal symptoms on their own — and to decide whether to continue, taper, or stop medications without adequate support.

For example, after years of treatment, significant behavioral and life changes, and months of contemplation, I recently began working with my prescriber to reduce my medication. I’ve been slowly tapering my dose of venlafaxine for the last few months and have now returned to the dose I was originally prescribed. Despite my steely resolve, the process has been difficult — fluctuating moods, low motivation, headaches, and the dreaded “brain zaps” that I’ve come to recognize as withdrawal. Continuing toward eventual cessation seems daunting.

What Experts Say About Deprescribing

While emerging guidelines are a start, the fact remains that there is little formal training in deprescribing education for providers. Unlike other areas of medicine, where medication reviews and step-down plans are more routine, mental health care rarely builds in regular reassessment with a goal of deprescribing. More tools to support equitable shared decision-making are needed.

Experts in psychiatry generally agree that the field has invested decades in developing and prescribing these medications. It is past time to invest similarly in understanding how to use them safely over the long term, and how to stop them when appropriate. This means:

– Developing clear, evidence-based tapering protocols

– Training clinicians to recognize and manage withdrawal symptoms

– Involving patients in shared decision-making from the start

– Conducting long-term studies on the effects of psychiatric medications beyond 12 weeks

The Risks of Staying on Medications Longer Than Necessary

This inertia has real consequences. Common and serious risks of psychotropic medications include weight gain, metabolic syndrome, sedation or mental fogginess, and drug-induced movement disorders such as tardive dyskinesia. Patients should not be subject to potential side effects longer than necessary, and especially not for medications for which the long-term health consequences are unknown.

For many patients, the decision to continue medication is not based on a careful risk-benefit analysis but on a lack of alternatives. Without a clear plan for discontinuation, patients may stay on medications for years without ever discussing whether they still need them.

Public Attention and the Need for Nuance

Public discourse, including recent comments from HHS Secretary Robert F. Kennedy Jr. questioning antidepressant prescribing practices, has brought renewed attention to these concerns. But this conversation should not devolve into simplistic pro- or anti-medication narratives. Psychiatric medications help many people, including me. The real issue is whether patients and clinicians have the evidence, guidance, and support needed to make informed decisions about long-term use and safe discontinuation.

The goal should not be to stop all medications, but to ensure that every prescription is accompanied by a thoughtful plan for reassessment and, when appropriate, discontinuation.

Practical Takeaways for Patients and Caregivers

If you are currently taking a psychiatric medication — or considering starting one — here are some steps you can take to ensure you have a more informed and balanced approach:

– Ask about an exit strategy from the start. When your doctor prescribes a medication, ask: “How will we know if I can stop this? What would a tapering plan look like?”

– Request regular medication reviews. At least once a year, ask your prescriber to review all your medications and discuss whether tapering is appropriate.

– Educate yourself about withdrawal symptoms. Know that symptoms like anxiety, insomnia, and “brain zaps” can be signs of withdrawal, not relapse. Keep a symptom diary to help your doctor distinguish between the two.

– Work with a supportive prescriber. If your doctor dismisses your concerns about stopping medication, consider seeking a second opinion from a psychiatrist who specializes in deprescribing.

– Taper slowly and under medical supervision. Never stop a psychiatric medication abruptly. Work with your doctor to create a gradual tapering plan that minimizes withdrawal symptoms.

– Consider non-medication supports. Therapy, lifestyle changes, peer support, and mindfulness practices can all play a role in managing mental health — and may reduce your need for medication over time.

What Needs to Change in Mental Health Care

To support this shift, we also need to invest in research on the long-term efficacy of psychotropic medications as well as their adverse effects and how to taper them safely. We cannot provide truly evidence-based care without robust data on how these medications are used — and discontinued — in the real world.

Clinicians should build regular medication reviews into care, with explicit discussion of whether tapering is appropriate. Patients should be informed from the outset about the challenges of discontinuation. And the field as a whole must move beyond the assumption that “starting medication” is the only plan.

Conclusion: Starting Medication Should Never Be the Only Plan

My own journey — from a teenager starting Prozac to a 40-year-old carefully tapering venlafaxine — illustrates the need for a more thoughtful approach. An exit strategy should be part of the conversation from the very beginning. Patients deserve to know not only how to start a medication, but how to stop it safely when the time is right. With better research, better training for clinicians, and more open conversations between patients and providers, we can move toward a model of mental health care that truly supports long-term well-being — whether that includes medication or not.

Source: MedPage Today